Jefferies Financial Group Inc. Makes New $42.41 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Jefferies Financial Group Inc. acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,800,000 shares of the company's stock, valued at approximately $42,408,000. Jefferies Financial Group Inc. owned approximately 1.77% of Dyne Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Barclays PLC boosted its holdings in Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock valued at $7,446,000 after acquiring an additional 128,246 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Dyne Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company's stock valued at $3,655,000 after acquiring an additional 4,236 shares during the last quarter. KBC Group NV boosted its holdings in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 11.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock valued at $508,000 after acquiring an additional 2,265 shares during the last quarter. Finally, abrdn plc bought a new position in Dyne Therapeutics in the fourth quarter valued at about $608,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DYN has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Chardan Capital restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. Scotiabank initiated coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price on the stock. Royal Bank of Canada restated an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, BMO Capital Markets initiated coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $46.85.

Dyne Therapeutics Trading Down 3.3%

Shares of NASDAQ:DYN traded down $0.40 during trading on Wednesday, hitting $11.70. 1,983,451 shares of the company's stock traded hands, compared to its average volume of 1,673,224. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -3.29 and a beta of 1.19. The company has a 50-day moving average price of $10.36 and a 200-day moving average price of $17.77.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 6,237 shares of company stock worth $77,760. Corporate insiders own 14.14% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.